273 related articles for article (PubMed ID: 32923171)
1. Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC).
Schimanski CC; Kasper S; Hegewisch-Becker S; Schröder J; Overkamp F; Kullmann F; Bechstein WO; Vöhringer M; Öllinger R; Lordick F; Heinemann V; Geißler M; Schulz-Abelius A; Bernhard H; Schön MR; Greil R; Galle P; Lang H; Schmidtmann I; Moehler M
Oncoimmunology; 2020 Aug; 9(1):1806680. PubMed ID: 32923171
[TBL] [Abstract][Full Text] [Related]
2. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.
Schimanski CC; Möhler M; Schön M; van Cutsem E; Greil R; Bechstein WO; Hegewisch-Becker S; von Wichert G; Vöhringer M; Heike M; Heinemann V; Peeters M; Kanzler S; Kasper S; Overkamp F; Schröder J; Seehofer D; Kullmann F; Linz B; Schmidtmann I; Smith-Machnow V; Gockel I; Lang H; Galle PR
BMC Cancer; 2012 Apr; 12():144. PubMed ID: 22494623
[TBL] [Abstract][Full Text] [Related]
3. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
4. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Butts C; Socinski MA; Mitchell PL; Thatcher N; Havel L; Krzakowski M; Nawrocki S; Ciuleanu TE; Bosquée L; Trigo JM; Spira A; Tremblay L; Nyman J; Ramlau R; Wickart-Johansson G; Ellis P; Gladkov O; Pereira JR; Eberhardt WE; Helwig C; Schröder A; Shepherd FA;
Lancet Oncol; 2014 Jan; 15(1):59-68. PubMed ID: 24331154
[TBL] [Abstract][Full Text] [Related]
5. Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3).
Moehler M; Folprecht G; Heinemann V; Holch JW; Maderer A; Kasper S; Hegewisch-Becker S; Schröder J; Overkamp F; Kullmann F; Bechstein WO; Vöhringer M; Öllinger R; Lordick F; Geißler M; Schulz-Abelius A; Linz B; Bernhard H; Paul A; Schmidtmann I; Potthoff K; Schimanski CC
Int J Cancer; 2022 Apr; 150(8):1341-1349. PubMed ID: 34807464
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.
Katakami N; Hida T; Nokihara H; Imamura F; Sakai H; Atagi S; Nishio M; Kashii T; Satouchi M; Helwig C; Watanabe M; Tamura T
Lung Cancer; 2017 Mar; 105():23-30. PubMed ID: 28236981
[TBL] [Abstract][Full Text] [Related]
7. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses.
Mitchell P; Thatcher N; Socinski MA; Wasilewska-Tesluk E; Horwood K; Szczesna A; Martín C; Ragulin Y; Zukin M; Helwig C; Falk M; Butts C; Shepherd FA
Ann Oncol; 2015 Jun; 26(6):1134-1142. PubMed ID: 25722382
[TBL] [Abstract][Full Text] [Related]
8. Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.
Rossmann E; Österborg A; Löfvenberg E; Choudhury A; Forssmann U; von Heydebreck A; Schröder A; Mellstedt H
Hum Vaccin Immunother; 2014; 10(11):3394-408. PubMed ID: 25483677
[TBL] [Abstract][Full Text] [Related]
9. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).
Lawson DH; Lee S; Zhao F; Tarhini AA; Margolin KA; Ernstoff MS; Atkins MB; Cohen GI; Whiteside TL; Butterfield LH; Kirkwood JM
J Clin Oncol; 2015 Dec; 33(34):4066-76. PubMed ID: 26351350
[TBL] [Abstract][Full Text] [Related]
10. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial.
Buisman FE; Homs MYV; Grünhagen DJ; Filipe WF; Bennink RJ; Besselink MGH; Borel Rinkes IHM; Bruijnen RCG; Cercek A; D'Angelica MI; van Delden OM; Donswijk ML; van Doorn L; Doornebosch PG; Emmering J; Erdmann JI; IJzerman NS; Grootscholten C; Hagendoorn J; Kemeny NE; Kingham TP; Klompenhouwer EG; Kok NFM; Koolen S; Kuhlmann KFD; Kuiper MC; Lam MGE; Mathijssen RHJ; Moelker A; Oomen-de Hoop E; Punt CJA; Te Riele WW; Roodhart JML; Swijnenburg RJ; Prevoo W; Tanis PJ; Vermaas M; Versleijen MWJ; Veuger FP; Weterman MJ; Verhoef C; Groot Koerkamp B
BMC Cancer; 2019 Apr; 19(1):327. PubMed ID: 30953467
[TBL] [Abstract][Full Text] [Related]
12. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
[TBL] [Abstract][Full Text] [Related]
13. Survival Benefit of and Indications for Adjuvant Chemotherapy for Resected Colorectal Liver Metastases-a Japanese Nationwide Survey.
Kobayashi S; Beppu T; Honda G; Yamamoto M; Takahashi K; Endo I; Hasegawa K; Kotake K; Itabashi M; Hashiguchi Y; Kotera Y; Sakamoto K; Yamaguchi T; Morita S; Tabuchi K; Miyazaki M; Sugihara K
J Gastrointest Surg; 2020 Jun; 24(6):1244-1260. PubMed ID: 31197683
[TBL] [Abstract][Full Text] [Related]
14. FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study.
Köhne CH; Poston G; Folprecht G; Ciardiello F; Ronga P; Beier F; Van Cutsem E
Eur J Surg Oncol; 2016 Oct; 42(10):1540-7. PubMed ID: 27575968
[TBL] [Abstract][Full Text] [Related]
15. Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol.
Boilève A; Maillard A; Wagner M; Dromain C; Laurent C; Dupont Bierre E; Le Sourd S; Audemar F; Ulusakarya A; Guerin-Meyer V; Smisth D; Pezzella V; De Baere T; Goere D; Gelli M; Taieb J; Boige V
BMC Cancer; 2020 Jan; 20(1):74. PubMed ID: 32000724
[TBL] [Abstract][Full Text] [Related]
16. CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial.
Froelich MF; Heinemann V; Sommer WH; Holch JW; Schoeppe F; Hesse N; Baumann AB; Kunz WG; Reiser MF; Ricke J; D'Anastasi M; Stintzing S; Modest DP; Kazmierczak PM; Hofmann FO
Eur Radiol; 2018 Dec; 28(12):5284-5292. PubMed ID: 29882070
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).
Singer CF; Pfeiler G; Hubalek M; Bartsch R; Stöger H; Pichler A; Petru E; Bjelic-Radisic V; Greil R; Rudas M; Maria Tea MK; Wette V; Petzer AL; Sevelda P; Egle D; Dubsky PC; Filipits M; Fitzal F; Exner R; Jakesz R; Balic M; Tinchon C; Bago-Horvath Z; Frantal S; Gnant M;
Eur J Cancer; 2020 Jun; 132():43-52. PubMed ID: 32325419
[TBL] [Abstract][Full Text] [Related]
19. Anatomic Resection Is Not Required for Colorectal Liver Metastases with RAS Mutation.
Joechle K; Vreeland TJ; Vega EA; Okuno M; Newhook TE; Panettieri E; Chun YS; Tzeng CD; Aloia TA; Lee JE; Vauthey JN
J Gastrointest Surg; 2020 May; 24(5):1033-1039. PubMed ID: 32162236
[TBL] [Abstract][Full Text] [Related]
20. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
